Why the study?
Galectin-3 is a biomarker of fibrosis linked to atrial remodeling, and recognizing such biomarkers in atrial fibrillation may improve clinical management.
Is Galectin-3 associated with atrial fibrosis in patients with atrial fibrillation?
Is Galectin-3 associated with atrial fibrosis in patients with atrial fibrillation?
Galectin-3 is significantly associated with atrial fibrosis in patients with all types of atrial fibrillation, including post-ablation, suggesting its utility as a biomarker for atrial remodeling.
May inform fibrosis risk stratification in AF; supports biomarker validation in prospective trials.
Galectin-3 (Gal-3) is a biomarker of fibrosis that has been associated with atrial remodeling. Acknowledging the presence of a biomarker in patients with atrial fibrillation (AF) can allow for a better clinical treatment. The aim of this study was to assess the association of Gal-3 with atrial fibrosis in patients with AF. This is a systematic review study. From the total number of studies analyzed, 12 demonstrated a relation between atrial fibrosis and Gal-3 in patients with AF and presented statistically significant association values. We conclude that Gal-3 is associated with atrial fibrosis in patients with AF in all types, as well as after the arrhythmia treatment by ablation.
No takes yet. Share an insight, caveat, or question.
Silveira et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: